# OnCo record paper-morpho-gilteritinib-levis-jco-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-morpho-gilteritinib-levis-jco-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-morpho-gilteritinib-levis-jco-2024" ;
  schema:name "MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia"@en ;
  schema:description "Two years of the FLT3 blocker gilteritinib after a stem-cell transplant did not significantly reduce relapses across all patients, but it clearly did in the half whose highly sensitive blood tests still found traces of the leukaemia, one of the first results to support choosing post-transplant treatment by residual disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-morpho-gilteritinib-levis-jco-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.23.02474>, <https://pubmed.ncbi.nlm.nih.gov/38471061/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.23.02474> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Levis MJ, Hamadani M, Logan B, et al." ;
  onco:cancers <https://onco.cc/cancers/aml-flt3/>, <https://onco.cc/cancers/aml/> ;
  onco:drugs <https://onco.cc/drugs/gilteritinib/> ;
  onco:trials <https://onco.cc/trials/morpho/> ;
  onco:journals <https://onco.cc/journals/jco/> .